title: Ligand-Binding Assay Development: What Do You Want to Measure Versus What You Are Measuring?
authors.affiliation: GlaxoSmithKline Pharmaceuticals Research and Development, 709 Swedeland Road, King of Prussia, Pennsylvania, 19406, USA. andrew.p.mayer@gsk.com.|Platform Technology and Science, DMPK-Bioanalytical Science and Toxicokinetics, King of Prussia, Pennsylvania, USA. andrew.p.mayer@gsk.com.
authors.forename: Andrew P
authors.identifier: http://orcid.org/0000-0003-0461-7756
authors.initials: AP
authors.lastname: Mayer
authors.affiliation: GlaxoSmithKline Pharmaceuticals Research and Development, 709 Swedeland Road, King of Prussia, Pennsylvania, 19406, USA.|Platform Technology and Science, DMPK-Bioanalytical Science and Toxicokinetics, King of Prussia, Pennsylvania, USA.
authors.forename: Charles S
authors.initials: CS
authors.lastname: Hottenstein
mesh_terms: D002626:Chemistry, Pharmaceutical / Q000379:methods*; D006801:Humans; D008024:Ligands; D004364:Pharmaceutical Preparations / Q000032:analysis* / Q000378:metabolism*; D011485:Protein Binding / Q000502:physiology
chemical_list: D008024:Ligands; D004364:Pharmaceutical Preparations
keywords: characterize; free/total; immunoassay; ligand-binding assays